The expansion of the worldwide auto-injectors market is anticipated to be boosted by an increase in inorganic methods like agreements. For instance, the Aidaptus auto-injector was the subject of a contract signed by Owen Mumford Ltd. and Stevanato Group in May 2022, the latter of which is a manufacturer and distributor of drug containment. By combining elite device expertise with top-notch production skills, this cooperation will benefit customers. The Aidaptus auto-injector is a two-step, single-use auto-injector with a flexible design that accepts both 1.25 mL and 2.25 mL prefilled glass syringes in the same base unit. The use of inorganic growth tactics, such as the launch of new products, is anticipated to fuel the global market for auto-injectors. For instance, Jabil Inc., a manufacturer of medical devices, declared in May 2022 that the Qfinity auto-injector was now available. It is a less expensive, self-administered, reusable, and modular method for subcutaneous (SC) medication delivery.
Coherent Market Insights projects that in 2022, the market for Auto-Injectors is projected to be worth US$4,497.7 million and is anticipated to grow at a CAGR of 18.0%. (2022-2030).
Key Competitors in the Auto Injectors Industry:
1. Eli Lilly And Company,
The company was founded in 1876 and has its main office in Indianapolis, Indiana. The business focuses on the development, promotion, and marketing of pharmaceuticals for use in treating patients. In October 2020, Disarm Therapeutics, which provides cutting-edge treatments for axonal degeneration, announced that Lilly would acquire it. In 2023, the company would reportedly concentrate on developing drugs for autoimmune diseases, diabetes, obesity, and Alzheimer's.
2. Takeda Pharmaceutical Company Limited
The business was established in 1781 and turned into a corporation on January 29, 1925. The main interests of the company include oncology, rare diseases, neurology, gastrointestinal, particle medicine, and vaccinations. Takeda fully purchased the TYK2 Program Subsidiary of Nimbus Therapeutics in February 2023. In October 2022, Takeda signed a cooperation and licencing deal with Zedira and Dr. Falk Pharma to create a first-in-class medication for celiac disease.
3. GSK plc
The firm was founded in 2000, and has its main office in London, England. Drugs for illnesses like insulin, cancer, worms, and psychological health are produced by GSK. In January 2022, the company reported getting three unsolicited offers to buy the Consumer Healthcare division of Unilever. GSK released optimistic Phase IIa research results in November 2022 for a novel, first-in-class prospective treatment for tuberculosis patients
4. Novartis AG
Novartis AG was founded in March 1996 and has offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Prescription drugs, over-the-counter drugs, immunisations, tests, eyeglasses, and veterinary medicine are all covered by Novartis. Handling, Marketing, Operations, and Research are a few of the activities that Novartis directly performs through its companies.
5. Teva Pharmaceutical Industries Ltd.
The company is headquartered in Tel Aviv, Israel, and was established in 1901. Although it specialises on generic drugs, it also has certain ancillary commercial interests in pharmaceutical active ingredients and, to a lesser extent, patented drugs. Teva's ambitious climate objectives will have received external validation on January 19, 2023, according to the Science Based Goals programme (SBTi). Teva declared on January 9th, 2023, that the federal opioids deal will move through following widespread state backing.
6. Mylan NV,
The firm, founded in 1961, has its headquarters in Canonsburg, Pennsylvania, United States. The business manufactures active pharmaceutical ingredients, has a specialist division devoted to respiratory, allergy, and psychiatric therapies, and is a global generic and specialty medicines company. While the coronavirus 2019 (COVID-19) pandemic continues to evolve, Mylan stated in July 2020 that its Remdesivir would be commercially released in India under the brand name DESREMTM.
7. Pfizer Inc.,
The company was established in 1849, and it is based in Manhattan, New York City. The medical specialties of immunology, cancer, the heart, endocrinology, and neurology are all benefited by Pfizer's research and production of drugs and vaccines. In October 2022, the company successfully purchased the calcitonin gene-related peptide programmes of Biohaven Pharma. In April 2021, Amplyx Pharmaceuticals and the antifungal medication fosmanogepix were acquired by Pfizer. (APX001).
8. AstraZeneca plc
The organisation was founded in 1999 and the company's headquarter is located in Cambridge, United Kingdom. Its product line includes treatments for inflammatory, viral, neurological, respiratory, and heart disease. AstraZeneca declared its intention to buy CinCor Pharma for $1.8 billion in January 2023. The business declared in July 2022 that it will buy TeneoTwo for up to $1.3 billion, expanding its line of blood cancer medications.
*Definition: An auto-injector is a medical tool that one uses to administer a single, preloaded dose of medication to themselves. It has a spring-loaded syringe that activates when the apparatus is firmly pressed on the body.
